Citations

Clear

75 citation(s) found for "Lee, Hong".

Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer's Disease
Li, Yan , Barthélemy, Nicolas R. , Gordon, Brian A. , Hassenstab, Jason , Fagan, Anne M. , Morris, John C. , Xiong, Chengjie , Méndez, Patricio Chrem, Noble, James M. , Farlow, Martin R. , Chhatwal, Jasmeer P. , Day, Gregory S. , Masters, Colin L. , Roh, Jee Hoon , Sachdev, Pallavi, Koyama, Akihiko , Reyderman, Larisa, Bateman, Randall J. , Network, and the Dominantly Inherited Alzheimer, Sachdev, Perminder S. , Vöglein, Jonathan , Gordon, Brian A , Kasuga, Kensaku , Day, Gregory S , Jucker, Mathias , Roh, Jee Hoon , Sato, Chihiro , McDade, Eric M , Sachdev, Perminder S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Hassenstab, Jason , Morris, John C , Noble, James M , Horie, Kanta , Li, Yan, Benzinger, Tammie L.S. , Karch, Celeste M. , Xiong, Chengjie , Allegri, Ricardo , Ikeuchi, Takeshi , Schofield, Peter R. , Lee, Jae‐Hong , Sachdev, Pallavi, McDade, Eric , Network, and the Dominantly Inherited Alzheimer

Mayo Clinic

Annals of Neurology | February 27, 2023 | Volume: 93 | Issue: 6 | Pages: 1158-1172

10.1002/ana.26620 | PMID 36843330 Get It

ObjectiveIdentifying cerebrospinal fluid measures of the microtubule binding region of tau (MTBR‐tau) species that reflect tau aggregation could provide fluid biomarkers that track Alzheimer's disease related neurofibrillary tau pathological changes. We examined the cerebrospinal fluid (CSF) MTBR‐tau species in dominantly inherited Alzheimer's disease (DIAD) mutation carriers to assess the association with Alzheimer's disease (AD) biomarkers and clinical symptoms.MethodsCross‐sectional and longitudinal CSF from 229 DIAD mutation carriers and 130 mutation non‐carriers had sequential characterization of N‐terminal/mid‐domain phosphorylated tau (p‐tau) followed by MTBR‐tau species and tau positron emission tomography (tau PET), other soluble tau and amyloid biomarkers, comprehensive clinical and cognitive assessments, and brain magnetic resonance imaging of atrophy.ResultsCSF MTBR‐tau species located within the putative “border” region and one species corresponding to the “core” region of aggregates in neurofibrillary tangles (NFTs) increased during the presymptomatic stage and decreased during the symptomatic stage. The “border” MTBR‐tau species were associated with amyloid pathology and CSF p‐tau; whereas the “core” MTBR‐tau species were associated stronger with tau PET and CSF measures of neurodegeneration. The ratio of the border to the core species provided a continuous measure of increasing amounts that tracked clinical progression and NFTs.InterpretationChanges in CSF soluble MTBR‐tau species preceded the onset of dementia, tau tangle increase, and atrophy in DIAD. The ratio of 4R‐specific MTBR‐tau (border) to the NFT (core) MTBR‐tau species corresponds to the pathology of NFTs in DIAD and change with disease progression. The dynamics between different MTBR‐tau species in the CSF may serve as a marker of tau‐related disease progression and target engagement of anti‐tau therapeutics. ANN NEUROL 2023;93:1158–1172
Brain network decoupling with increased serum neurofilament and reduced cognitive function in Alzheimer’s disease
Wheelock, Muriah D. , Strain, Jeremy F. , Mansfield, Patricia K. , Tu, Jiaxin Cindy , Tanenbaum, Aaron , Preische, Oliver, Chhatwal, Jasmeer P. , Cash, David M. , Fagan, Anne M. , Fox, Nick C. , Graff‐Radford, Neill R. , Hassenstab, Jason , Jack, Clifford R. , Xiong, Chengjie , Perrin, Richard J. , Xiong, Chengjie , Morris, John C. , Ances, Beau M. , Eggebrecht, Adam T. , Gordon, Brian A. , Network, the Dominantly Inherited Alzheimer, Adams, Sarah , Araki, Aki, Barthélemy, Nicolas R. , Bechara, Jacob , Berman, Sarah , Bodge, Courtney, Brandon, Susan E. , Brooks, W. K. , Brosch, Jared R. , Buck, Jill , Buckles, Virginia, Cash, Lisa, Chen, Charlie, Chrem, Patricio, Chua, Jasmin, Chui, Helena, Cruchaga, Carlos , Day, Gregory S. , Cruz, Chrismary De La, Denner, Darcy, Diffenbacher, Anna, Dincer, Aylin , Donahue, Tamara, Egido, Noelia , Esposito, Bianca, Farlow, Marty, Feldman, Becca , Fitzpatrick, Colleen , Franklin, Erin , Friedrichsen, Nelly, Gardener, Samantha L. , Goate, Alison , Goldberg, Sarah B. , Gonzalez, Alyssa, Gräber‐Sultan, Susanne, Graham, Morgan, Gray, Julia, Gremminger, Emily, Groves, Alex, Haass, Christian , Häsler, Lisa M., Hellm, Cortaiga, Herries, Elizabeth, Hoechst-Swisher, Laura, Hornbeck, Russ C. , Igor, Yakushev, Ihara, Ryoko , Ikonomović, Snežana, Ishii, Kenji , Jerome, Gina, Käser, Stephan, Keefe, Sarah , Klunk, William E. , Koudelis, Deb, Kuder-Buletta, Elke, Laske, Christoph , Martinez, Rita, Mason, Neal Scott, Mawuenyega, Kwasi G., Mejia, Arlene, Morenas‐Rodríguez, Estrella , Mori, Hiroshi , Mountz, James M. , Mummery, Cath, Nadkami, Neelesh, Nagamatsu, Akemi, Neimeyer, Katie, Norton, Joanne, Nuscher, Brigitte , Obermüller, Ulricke, Patira, Riddhi , Ping, Lingyan, Ringman, John M. , Salloway, Stephen , Senda, Michio , Seyfried, Nick , Shady, Kristine, Sigurdson, Wendy, Smith, Lori, Snitz, Beth E. , Sohrabi, Hamid R. , Stephens, Sochenda, Taddei, Kevin , Thompson, Sarah , Vöglein, Jonathan , Wang, Peter, Weamer, Elise A., Xu, Jinbin , Cruchaga, Carlos , Fagan, Anne M , Fox, Nick C , Graff-Radford, Neill R , Hassenstab, Jason , Jack, Clifford R , Karch, Celeste M , Xiong, Chengjie , McDade, Eric M , Schofield, Peter R , Xiong, Chengjie , Morris, John C , Bateman, Randall J , Jucker, Mathias , Benzinger, Tammie L S , Ances, Beau M , Eggebrecht, Adam T , Gordon, Brian A , Cruchaga, Carlos , Day, Gregory S , Vöglein, Jonathan , Cash, David M , Goate, Alison M , Berman, Sarah , Karch, Celeste M. , McDade, Eric , Schofield, Peter R. , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, the Dominantly Inherited Alzheimer, Allegri, Ricardo , Brandon, Susan, Brooks, William (Bill), Buck, Jill, Carter, Kathleen, Douglas, Jane, Duong, Duc M , Feldman, Becca, Fitzpatrick, Colleen, Flores, Shaney , Fujii, Hisako , Ghetti, Bernardino , Goldman, Jill , Grilo, Miguel, Hofmann, Anna, Holtzman, David M. , Ikeuchi, Takeshi , Johnson, Erik C. B. , Kasuga, Kensaku , Koeppe, Robert A. , Lee, Jae‐Hong , Levey, Allan I. , Li, Yan , López, Oscar L. , Marsh, Jacob, Martins, Ralph N. , Masters, Colin L. , McCullough, Austin , Niimi, Yoshiki , Noble, James M. , O’Connor, Antoinette , Ping, Lingyan, Renton, Alan , Sánchez‐Valle, Raquel , Shimada, Hiroyuki , Smith, Jennifer A. , Thompson, Sarah, Wang, Qing , Xu, Xiong

Mayo Clinic

Brain | January 10, 2023 | Volume: 146 | Issue: 7 | Pages: 2928-2943

10.1093/brain/awac498 | PMID 36625756 Get It

Abstract Neurofilament light chain, a putative measure of neuronal damage, is measurable in blood and CSF and is predictive of cognitive function in individuals with Alzheimer’s disease. There has been limited prior work linking neurofilament light and functional connectivity, and no prior work has investigated neurofilament light associations with functional connectivity in autosomal dominant Alzheimer’s disease. Here, we assessed relationships between blood neurofilament light, cognition, and functional connectivity in a cross-sectional sample of 106 autosomal dominant Alzheimer’s disease mutation carriers and 76 non-carriers. We employed an innovative network-level enrichment analysis approach to assess connectome-wide associations with neurofilament light. Neurofilament light was positively correlated with deterioration of functional connectivity within the default mode network and negatively correlated with connectivity between default mode network and executive control networks, including the cingulo-opercular, salience, and dorsal attention networks. Further, reduced connectivity within the default mode network and between the default mode network and executive control networks was associated with reduced cognitive function. Hierarchical regression analysis revealed that neurofilament levels and functional connectivity within the default mode network and between the default mode network and the dorsal attention network explained significant variance in cognitive composite scores when controlling for age, sex, and education. A mediation analysis demonstrated that functional connectivity within the default mode network and between the default mode network and dorsal attention network partially mediated the relationship between blood neurofilament light levels and cognitive function. Our novel results indicate that blood estimates of neurofilament levels correspond to direct measurements of brain dysfunction, shedding new light on the underlying biological processes of Alzheimer’s disease. Further, we demonstrate how variation within key brain systems can partially mediate the negative effects of heightened total serum neurofilament levels, suggesting potential regions for targeted interventions. Finally, our results lend further evidence that low-cost and minimally invasive blood measurements of neurofilament may be a useful marker of brain functional connectivity and cognitive decline in Alzheimer’s disease.
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition
Chatterjee, Pratishtha , Vermunt, Lisa , Gordon, Brian A. , Boonkamp, Lynn , Armstrong, Nicola J. , Xiong, Chengjie , Singh, Abhay Kumar , Li, Yan , Sohrabi, Hamid R. , Taddei, Kevin , Molloy, Mark P. , Morris, John C. , Berman, Sarah , Chhatwal, Jasmeer P. , Graff‐Radford, Neill R. , Day, Gregory S. , Farlow, Martin R. , Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Mori, Hiroshi , Perrin, Richard J. , Levey, Allan I. , Masters, Colin L. , Fagan, Anne M. , Bateman, Randall J. , Martins, Ralph N. , Network, and the Dominantly Inherited Alzheimer, Vöglein, Jonathan , Gordon, Brian A , Day, Gregory S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Levey, Allan I , Pedrini, Steve , Xiong, Chengjie , Benzinger, Tammie L.S. , Karch, Celeste M. , Cruchaga, Carlos , Lee, Jae‐Hong , McDade, Eric , Sánchez‐Valle, Raquel , Schofield, Peter R. , Jucker, Mathias , Teunissen, Charlotte E. , Network, and the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | December 28, 2022 | Volume: 19 | Issue: 7 | Pages: 2790-2804

10.1002/alz.12879 | PMID 36576155 Get It

Abstract Background Glial fibrillary acidic protein (GFAP) is a promising candidate blood‐based biomarker for Alzheimer's disease (AD) diagnosis and prognostication. The timing of its disease‐associated changes, its clinical correlates, and biofluid‐type dependency will influence its clinical utility. Methods We evaluated plasma, serum, and cerebrospinal fluid (CSF) GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Results Plasma GFAP elevations appear a decade before expected symptom onset, after amyloid beta (Aβ) accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished Aβ‐positive from Aβ‐negative ADAD participants and showed a stronger relationship with Aβ load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Conclusion Our findings support a role for plasma GFAP as a clinical biomarker of Aβ‐related astrocyte reactivity that is associated with cognitive decline and neurodegeneration. Highlights Plasma glial fibrillary acidic protein (GFAP) elevations appear a decade before expected symptom onset in autosomal dominant Alzheimer's disease (ADAD). Plasma GFAP was associated to amyloid positivity in asymptomatic ADAD. Plasma GFAP increased with clinical severity and predicted disease progression. Plasma and serum GFAP carried similar information in ADAD, while cerebrospinal fluid GFAP did not.
Progressive white matter injury in autosomal dominant Alzheimer’s disease is strongly associated with cerebral microbleeds and neurodegeneration
Shirzadi, Zahra , Yau, Wai‐Ying Wendy , Preboske, Gregory M., Farlow, Martin R. , Fagan, Anne M. , Fitzpatrick, Colleen , Salloway, Stephen , Perrin, Richard J. , Graff‐Radford, Neill R. , Koeppe, Robert, Chui, Helena C., Mori, Hiroshi , Johnson, Keith A., Greenberg, Steven M. , Chhatwal, Jasmeer P. , Investigators, DIAN, Schultz, Stephanie A. , Joseph‐Mathurin, Nelly , Kantarci, Kejal , Jack, Clifford R. , Hassenstab, Jason , Jucker, Mathias , Morris, John C. , Xiong, Chengjie , Karch, Celeste M. , Levey, Allan I. , Gordon, Brian A. , Schofield, Peter William , McDade, Eric , Xiong, Chengjie , Cruchaga, Carlos , Allegri, Ricardo , Fox, Nick C. , Goate, Alison , Noble, James M. , Chui, Helena C. , Berman, Sarah , Sánchez‐Valle, Raquel , Lee, Jae‐Hong , Rosa-Neto, Pedro , Benzinger, Tammie L.S. , Sohrabi, Hamid R. , Martins, Ralph N. , Schultz, Aaron P. , Bateman, Randall J. , Johnson, Keith A. , Sperling, Reisa Anne , Investigators, DIAN

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.066715 Get It

AbstractBackgroundWhite matter (WM) injury visible on MRI is a common finding in Alzheimer’s disease (AD) and is often attributed to small vessel ischemic changes secondary to increased systemic vascular risk. Increased WM injury has been associated with the progression of Autosomal Dominant AD (ADAD), though ADAD pathogenic variant carriers are relatively young and may not have elevated vascular risk factors. We hypothesized that WM injury in ADAD may reflect worsening of cerebral amyloid angiopathy (CAA) and neurodegeneration. Here we examine this hypothesis using cross‐sectional and longitudinal data from the Dominantly Inherited Alzheimer Network observational study (DIAN).MethodMRI data from ADAD pathogenic variant carriers (n=223) and non‐carriers (n=136) were used in the present study (Table 1). We extracted FreeSurfer‐based WM lesion (WML) volume from T1‐weighted images (hypointensities). Cortical microbleed (CMB) burden was assessed visually on susceptibility weighted/T2*‐weighted gradient echo images by experienced radiologists (blineded to the mutation status) at the Mayo Clinic in Rochester. Linear regression models compared WML volume at baseline in people with and without CMB. Linear mixed effect models assessed the relationships between longitudinal WML and both CMBs and FreeSurfer‐based total gray matter (GM) volume. Models were corrected for age and estimated years to symptom onset (EYO).ResultGreater baseline WML volume was seen in ADAD carriers vs. non‐carriers, particularly close to the age of estimated symptom onset. Baseline WML volume was greater in carriers with CMBs compared to those without (t=2.9, p=0.003, Figure 1). Longitudinal increase in WML amongst ADAD pathogenic variant carriers with CMBs was estimated to be 214 mm3/year greater than that amongst carriers without CMBs (t=4.1, p<0.001, Figure 2). Independent of this CMB effect, decreasing GM volume was strongly associated with increasing longitudinal WML volume (t=‐6.2, p<0.001, Figure 3). Similar analyses in the non‐carrier group yielded no significant findings.ConclusionConsistent with prior reports, WML volume was increased in ADAD pathogenic variant carriers. However, the results here suggest WML in ADAD may not solely be due to small vessel ischemic changes, but rather may be a result of worsening CAA and more rapid neurodegeneration.
Comparison of amyloid accumulation between Down syndrome and autosomal‐dominant Alzheimer disease
Boerwinkle, Anna H. , Henson, Rachel L. , Butt, Omar H. , Chen, Charles D., Fagan, Anne M. , Christian, Bradley T. , Mapstone, Mark , Price, Julie C. , Schupf, Nicole , Laymon, Charles M. , Krinsky‐McHale, Sharon J. , Lai, Florence , Rosas, H. Diana , Lott, Ira T. , Silverman, Wayne , Chhatwal, Jasmeer P. , Chui, Helena C., Farlow, Martin R. , Graff‐Radford, Neill R. , Mori, Hiroshi , Perrin, Richard J. , Salloway, Stephen , Xiong, Chengjie , Gordon, Brian A. , Wisch, Julie K. , Flores, Shaney , Benzinger, Tammie L.S. , Handen, Benjamin L. , Head, Elizabeth , Klunk, William E. , Rafii, Michael S. , O’Bryant, Sid E. , Hartley, Sigan L. , Zaman, Shahid H. , Brickman, Adam M. , Lee, Joseph H. , Allegri, Ricardo , Berman, Sarah , Chui, Helena C. , Cruchaga, Carlos , Fox, Nick C. , Goate, Alison , Day, Gregory S. , Jucker, Mathias , Lee, Jae‐Hong , Xiong, Chengjie , Martins, Ralph N. , Sánchez‐Valle, Raquel , Schofield, Peter R. , Karch, Celeste M. , Hassenstab, Jason , McDade, Eric , Bateman, Randall J. , Ances, Beau M.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.064684 Get It

AbstractBackgroundGiven the triplication of chromosome 21 and the location of the amyloid precursor protein gene on chromosome 21, almost all adults with Down syndrome (DS) develop Alzheimer disease (AD)‐like pathology and dementia during their lifetime. Comparing amyloid accumulation in DS to autosomal dominant AD (ADAD), another genetic form of AD, may improve our understanding of early AD pathology development.MethodWe assessed amyloid positron emission tomography (PET) imaging in 192 participants with DS and 33 sibling controls from the Alzheimer’s Biomarker Consortium‐Down Syndrome (ABC‐DS) and 265 mutation‐carriers (MC) and 169 familial controls from the Dominantly Inherited Alzheimer Network (DIAN) (Table 1). We calculated regional standard uptake value ratios (SUVR) using a cerebellar cortex reference region and converted global amyloid burden SUVR to centiloids. We compared amyloid PET by cognitive status and estimated‐years‐to‐symptom‐onset (EYO). EYO was calculated for DIAN participants by subtracting their age from parental age of symptom onset and for ABC‐DS participants by subtracting their age from 50.2 years, a published average age of symptom onset in a large sample of individuals with DS (Fortea et al., 2020). In a subset of participants, we assessed the relationship between amyloid PET and CSF Aβ42/40.ResultThe relationship between CSF Aβ42/40 and amyloid PET was similar in DS and MC participants (Figure 1). We did not observe significant differences between MC and DS grouped by cognitive status (Figure 2). However, when assessed over EYO, global amyloid burden was significantly elevated in MC at EYO ≥ ‐23 but was not elevated in DS until EYO ≥ ‐15 (Figure 3). We observed early cortical and subcortical amyloid PET increases in both groups, but we also measured some regional differences in amyloid PET changes between MC and DS, specifically in the medial occipital region (Figure 4 and 5).ConclusionThese results demonstrate similarities in the relationship between amyloid biomarkers and the levels of amyloid accumulation in ADAD and DS. However, we also observed a 5‐10 year delay and some regional differences in amyloid accumulation in DS. This is important for future clinical trials to consider when recruiting participants and determining treatment efficacy.
AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains
Fagan, Anne M. , Chen, Charles D., Fitzpatrick, Colleen , Chui, Helena C., Mori, Hiroshi , Johnson, Keith A., Farlow, Martin R. , Farrell, Michelle E. , Graff‐Radford, Neill R. , Perrin, Richard J. , Salloway, Stephen , Shirzadi, Zahra , Chhatwal, Jasmeer P. , Schultz, Stephanie A. , Allegri, Ricardo , Schultz, Aaron P. , Goate, Alison , Levey, Allan I. , Hanseeuw, Bernard , Koeppe, Robert A. , Gordon, Brian A. , Cruchaga, Carlos , Karch, Celeste M. , Xiong, Chengjie , Jack, Clifford R. , McDade, Eric , Chui, Helena C. , Lee, Jae‐Hong , Noble, James M. , Hassenstab, Jason , Xiong, Chengjie , Morris, John C. , Johnson, Keith A. , Liu, Lei , Jucker, Mathias , Joseph‐Mathurin, Nelly , Fox, Nick C. , Schofield, Peter R. , Martins, Ralph N. , Sánchez‐Valle, Raquel , Berman, Sarah , Rosa-Neto, Pedro , Benzinger, Tammie L.S. , Bateman, Randall J. , Sperling, Reisa Anne

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S4 | Pages: No page available

10.1002/alz.067186 Get It

AbstractBackgroundRates of cognitive and biomarker change in Autosomal Dominant Alzheimer disease (ADAD) vary substantially across individuals. Prior cross‐sectional work suggests that the location of the pathogenic variant within PSEN1, specifically whether the underlying variant affects transmembrane (TM) or cytoplasmic (CY) domains in PSEN1, may be a key determinant in these differential rates of progression. Here we use longitudinal data from the Dominantly Inherited Alzheimer Network observational study (DIAN‐Obs) to examine whether variants affecting TM versus CY domains in PSEN1 have differential rates of change in key cognitive and neurodegenerative markers, and whether these differences are relevant to ADAD clinical trials.MethodsUsing longitudinal clinical, cognitive, and MRI data from PSEN1 pathogenic variant carriers [TM group N=76 and CY group N=44; Table 1], we assessed rates of change in Mini‐Mental State Exam (MMSE), Clinical Dementia Rating® Sum of Boxes (CDR®‐SOB), and hippocampal volume (HV) using linear mixed effects models accounting for disease stage (estimated years to symptom onset [EYO]). We further assessed how PSEN1 mutation location (TM versus CY) impacts sample size and detectable effect size in a potential ADAD clinical trial (modeled as a 4‐year trial with annual assessments; 80% power; α = 0.05).ResultsPSEN1 TM and PSEN1 CY groups did not differ on baseline age, EYO, or CDR®. The PSEN1 TM group had significantly greater rates of change on MMSE (B[SE] = ‐0.42[0.1], p=0.002), CDR®‐SOB (B[SE] = 0.23[0.1], p=0.001), and HV atrophy (B[SE] = ‐58.93[14.3], p=0.0006 compared to the PSEN1 CY group (Fig.1). Consistent with these differential rates of change, power analyses indicated the required sample size to detect a 30% treatment effect on MMSE or HV would be reduced by 59.6% for MMSE and 91.0% for HV for a trial population comprised of PSEN1 TM versus CY carriers (Fig.2).ConclusionsIndividuals who had a variant affecting the transmembrane domains of PSEN1 had greater rates of cognitive decline and neurodegeneration compared to those with variants affecting cytoplasmic domains. In addition to having implications for ADAD pathophysiology, these results suggest that incorporating information regarding the location of PSEN1 variants may be beneficial in analyzing and designing stratification approaches for ADAD trials.
AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains.
Schultz, Stephanie A. , Fagan, Anne M. , Hanseeuw, Bernard , Gordon, Brian A. , Chen, Charles D., Xiong, Chengjie , Fitzpatrick, Colleen , Chui, Helena C., Mori, Hiroshi , Morris, John C. , Johnson, Keith A., Liu, Lei , Farlow, Martin R. , Farrell, Michelle E. , Graff‐Radford, Neill R. , Perrin, Richard J. , Berman, Sarah , Salloway, Stephen , Shirzadi, Zahra , Bateman, Randall J. , Chhatwal, Jasmeer P. , Gordon, Brian A , Bateman, Randall J , Xiong, Chengjie , Morris, John C , Berman, Sarah , Allegri, Ricardo , Schultz, Aaron P. , Goate, Alison , Levey, Allan I. , Koeppe, Robert A. , Cruchaga, Carlos , Karch, Celeste M. , Xiong, Chengjie , Jack, Clifford R. , McDade, Eric , Chui, Helena C. , Lee, Jae‐Hong , Noble, James M. , Hassenstab, Jason , Johnson, Keith A. , Jucker, Mathias , Joseph‐Mathurin, Nelly , Fox, Nick C. , Schofield, Peter R. , Martins, Ralph N. , Sánchez‐Valle, Raquel , Rosa-Neto, Pedro , Benzinger, Tammie L.S. , Sperling, Reisa Anne

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S1 | Pages: No page available

10.1002/alz.068221 Get It

AbstractBackgroundRates of cognitive and biomarker change in Autosomal Dominant Alzheimer disease (ADAD) vary substantially across individuals. Prior cross‐sectional work suggests that the location of the pathogenic variant within PSEN1, specifically whether the underlying variant affects transmembrane (TM) or cytoplasmic (CY) domains in PSEN1, may be a key determinant in these differential rates of progression. Here we use longitudinal data from the Dominantly Inherited Alzheimer Network observational study (DIAN‐Obs) to examine whether variants affecting TM versus CY domains in PSEN1 have differential rates of change in key cognitive and neurodegenerative markers, and whether these differences are relevant to ADAD clinical trials.MethodsUsing longitudinal clinical, cognitive, and MRI data from PSEN1 pathogenic variant carriers [TM group N=76 and CY group N=44; Table 1], we assessed rates of change in Mini‐Mental State Exam (MMSE), Clinical Dementia Rating® Sum of Boxes (CDR®‐SOB), and hippocampal volume (HV) using linear mixed effects models accounting for disease stage (estimated years to symptom onset [EYO]). We further assessed how PSEN1 mutation location (TM versus CY) impacts sample size and detectable effect size in a potential ADAD clinical trial (modeled as a 4‐year trial with annual assessments; 80% power; α = 0.05).Results PSEN1 TM and PSEN1 CY groups did not differ on baseline age, EYO, or CDR®. The PSEN1 TM group had significantly greater rates of change on MMSE (B[SE] = ‐0.42[0.1], p=0.002), CDR®‐SOB (B[SE] = 0.23[0.1], p=0.001), and HV atrophy (B[SE] = ‐58.93[14.3], p=0.0006 compared to the PSEN1 CY group (Fig.1). Consistent with these differential rates of change, power analyses indicated the required sample size to detect a 30% treatment effect on MMSE or HV would be reduced by 59.6% for MMSE and 91.0% for HV for a trial population comprised of PSEN1 TM versus CY carriers (Fig.2).ConclusionsIndividuals who had a variant affecting the transmembrane domains of PSEN1 had greater rates of cognitive decline and neurodegeneration compared to those with variants affecting cytoplasmic domains. In addition to having implications for ADAD pathophysiology, these results suggest that incorporating information regarding the location of PSEN1 variants may be beneficial in analyzing and designing stratification approaches for ADAD trials.
Comparison of amyloid accumulation between Down syndrome and autosomal‐dominant Alzheimer disease
Boerwinkle, Anna H. , Henson, Rachel L. , Butt, Omar H. , Chen, Charles D., Fagan, Anne M. , Christian, Bradley T. , Mapstone, Mark , Price, Julie C. , Schupf, Nicole , Laymon, Charles M. , Krinsky‐McHale, Sharon J. , Lai, Florence , Rosas, H. Diana , Lott, Ira T. , Silverman, Wayne , Chhatwal, Jasmeer P. , Chui, Helena C., Farlow, Martin R. , Graff‐Radford, Neill R. , Mori, Hiroshi , Perrin, Richard J. , Salloway, Stephen , Gordon, Brian A. , Wisch, Julie K. , Flores, Shaney , Benzinger, Tammie L.S. , Handen, Benjamin L. , Head, Elizabeth , Klunk, William E. , Rafii, Michael S. , O’Bryant, Sid E. , Hartley, Sigan L. , Zaman, Shahid H. , Brickman, Adam M. , Lee, Joseph H. , Allegri, Ricardo , Berman, Sarah , Chui, Helena C. , Cruchaga, Carlos , Fox, Nick C. , Goate, Alison , Day, Gregory S. , Jucker, Mathias , Lee, Jae‐Hong , Xiong, Chengjie , Martins, Ralph N. , Sánchez‐Valle, Raquel , Schofield, Peter R. , Xiong, Chengjie , Karch, Celeste M. , Hassenstab, Jason , McDade, Eric , Bateman, Randall J. , Ances, Beau M.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S1 | Pages: No page available

10.1002/alz.063959 Get It

AbstractBackgroundGiven the triplication of chromosome 21 and the location of the amyloid precursor protein gene on chromosome 21, almost all adults with Down syndrome (DS) develop Alzheimer disease (AD)‐like pathology and dementia during their lifetime. Comparing amyloid accumulation in DS to autosomal dominant AD (ADAD), another genetic form of AD, may improve our understanding of early AD pathology development.MethodWe assessed amyloid positron emission tomography (PET) imaging in 192 participants with DS and 33 sibling controls from the Alzheimer’s Biomarker Consortium‐Down Syndrome (ABC‐DS) and 265 mutation‐carriers (MC) and 169 familial controls from the Dominantly Inherited Alzheimer Network (DIAN) (Table 1). We calculated regional standard uptake value ratios (SUVR) using a cerebellar cortex reference region and converted global amyloid burden SUVR to centiloids. We compared amyloid PET by cognitive status and estimated‐years‐to‐symptom‐onset (EYO). EYO was calculated for DIAN participants by subtracting their age from parental age of symptom onset and for ABC‐DS participants by subtracting their age from 50.2 years, a published average age of symptom onset in a large sample of individuals with DS (Fortea et al., 2020). In a subset of participants, we assessed the relationship between amyloid PET and CSF Aβ42/40.ResultThe relationship between CSF Aβ42/40 and amyloid PET was similar in DS and MC participants (Figure 1). We did not observe significant differences between MC and DS grouped by cognitive status (Figure 2). However, when assessed over EYO, global amyloid burden was significantly elevated in MC at EYO ≥ ‐23 but was not elevated in DS until EYO ≥ ‐15 (Figure 3). We observed early cortical and subcortical amyloid PET increases in both groups, but we also measured some regional differences in amyloid PET changes between MC and DS, specifically in the medial occipital region (Figure 4 and 5).ConclusionThese results demonstrate similarities in the relationship between amyloid biomarkers and the levels of amyloid accumulation in ADAD and DS. However, we also observed a 5‐10 year delay and some regional differences in amyloid accumulation in DS. This is important for future clinical trials to consider when recruiting participants and determining treatment efficacy.
Echocardiography in the Assessment of Valve Regurgitation– Incremental Role of Three Dimensional Echocardiography
Lee, Hong Seok , Naqvi, Tasneem Z.

Mayo Clinic

Reviews in Cardiovascular Medicine | December 16, 2022 | Volume: 23 | Issue: 12 | Pages: No page available

10.31083/j.rcm2312407 | PMID 39076660 Get It

Echocardiography (Echo) has a primary role in the evaluation of cardiac valve regurgitation. Echo valve regurgitation assessment includes multiple qualitative and quantitative methods which require adequate image quality, comprehensive echocardiographic images and precise measurements to obtain accurate assessment. For patient management, it is also important to investigate the mechanism of valve regurgitation. Severity and mechanism of valve regurgitation determine whether continued medical follow up is optimal or surgical or percutaneous valve repair, or replacement option should be necessary. Transthoracic Echo (TTE) is the gold standard most commonly used for the assessment of valve leaflet anatomy, valve motion and regurgitation severity to determine primary versus secondary causes of valve regurgitation, however transesophageal echo (TEE) provides high resolution imaging of valve leaflets and supporting apparatus and oftentimes determines mechanism of valve regurgitation particularly for mitral and tricuspid valves when TTE is unable to determine the mechanism. By providing surgical type views in a moving heart under normal hemodynamic conditions, 3D TEE has greatly improved assessment of mechanism and etiology of valve regurgitation. Besides, TEE also allows quantitation of valve regurgitation severity by Doppler methods as well as direct 3D planimetry of valve area and regurgitant orifice area. Doppler methods are pre and afterload dependent whereas direct 3D planimetry allows assessment of location and severity of valve regurgitation irrespective of ventricular loading conditions. Pre or intraoperative 3D TEE assessment can provide valuable information for surgical planning of valve repair or replacement. This review discusses various valvular pathologies causing regurgitation and the role of TTE and TEE in improving this assessment as shown by several case examples.